Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($) |
3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2022 |
Mar. 31, 2021 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
Research And Development Expenses | $ 3,600,000.0 | $ 3,900,000.0 | ||
Cash And Cash Equivalent | 23,732,379 | $ 33,061,711 | $ 20,581,313 | $ 19,444,737 |
Deferred Revenue | 10,000,000 | 12,512 | ||
Accounts Receivable | $ 72,371 | $ 12,510 | ||
Warrants And Options [Member] | ||||
Potentially Dilutive Securities Excluded From The Computation Of Eps | 6,346,268 | |||
Money Market Funds [Member] | ||||
Cash And Cash Equivalent | $ 10,200,000.0 |
X | ||||||||||
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|